Peptide handling
Selank reconstitution calculator
Reconstitution calculator for Selank, prefilled for its 5 and 10 mg vials. Get the concentration, the dose volume and the U-100 syringe reading.
Start from a compound
Fills the vial size and a starting water volume. Only compounds with a citable range fill a dose.
The second is the question asked once the syringe is already filled, or when checking a vial someone else reconstituted.
1 mg = 1,000 mcg. Published figures are usually micrograms; vial labels are milligrams.
- Draw to
- 10 unitson a U-100 syringe
- Dose
- 250 mcg
- Dose volume
- 0.1 mL
- Concentration
- 2.5 mg/mL
- Per unit
- 25 mcg
- Doses per vial
- 20whole doses; a partial one is not counted
Shown on a 30-unit (0.3 mL) U-100 syringe, the smallest that holds this draw.
Selank — Limited human data
From human studies that are small, early-phase, or for a different indication than the one this range is usually cited for. The prefilled dose is the low end of that range, daily, in 4-week cycles with rest periods between.
Vial size and water volume are a starting point for the arithmetic, not a recommendation.
Adding more water makes the same dose a larger, easier-to-read mark on the syringe. It does not change how many doses the vial holds.
Vial sizes and starting volume
Selank is commonly supplied in 5 mg and 10 mg vials. The calculator opens on a 5 mg vial with 2 mL of bacteriostatic water — a starting point for the arithmetic, not a recommendation. Change either and everything recalculates.
That combination gives 2.5 mg/mL, so one insulin unit holds 25 mcg and a 250 mcg dose is 10 units.
What dose to enter
A range of 250–500 mcg per dose can be cited for Selank, daily, in 4-week cycles with rest periods between. The dose field opens at the low end of it.
Limited human data
From human studies that are small, early-phase, or for a different indication than the one this range is usually cited for.
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. — Human clinical study. Human clinical study of Selank in generalized anxiety disorder and neurasthenia.
- A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. — Human comparative clinical study. Human trial comparing Selank to a benzodiazepine in patients with anxiety disorders.
- Optimization of the treatment of anxiety disorders with selank. — Human clinical study. Further human treatment-optimization study for anxiety disorders.
- Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. — Human clinical study. Human patient study on immunomodulatory effects, secondary to the anxiolytic use above.
- GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. — In vitro cell study. In vitro cell-line study on gene expression; not a human dosing study.
Related
- Selank — the product page, with its current batch.
- Bacteriostatic water — what goes in the vial.
- Peptide reconstitution calculator — the general version, with the blend and half-life calculators alongside it.
- Dosing reference — published schedules, each with the evidence behind it.
For research use only. This tool performs arithmetic on figures you supply — it is not medical guidance and does not recommend a dose for any compound.